Source comparison
Sermorelin for Telehealth Clinicians: Clinical Outcome vs Research Application Comparison
Clinical GH Deficiency (Telehealth Rx) 200–500 mcg SC nightly IGF-1 levels, lean mass via DEXA, symptom improvement scales IGF-1 retest at 8–12 weeks, clinical assessment every 3 months Requires baseline IGF-1 <150 ng/mL (men) or <170 ng/mL (women aged 40–50),
This comparison does not assign a generated winner or score.
- Clinical GH Deficiency (Telehealth Rx)
- 200–500 mcg SC nightly
- IGF-1 levels, lean mass via DEXA, symptom improvement scales
- IGF-1 retest at 8–12 weeks, clinical assessment every 3 months
- Requires baseline IGF-1 <150 ng/mL (men) or <170 ng/mL (women aged 40–50), documented symptom burden, and exclusion of thyroid/anemia/vitamin D deficiency. Prescribing without this justification creates board-level risk
- Research Application (Lab/Preclinical)
- Variable (often 50–200 mcg for cell culture models)
- GH secretion assay, receptor binding affinity, peptide stability under storage conditions
- Per experimental protocol. Not patient-facing
- Research-grade sermorelin at 95% purity is adequate for lab use but insufficient for human administration. Real Peptides distinguishes pharmaceutical-grade (≥98% purity, endotoxin <5 EU/mg) from research-grade explicitly
- Off-Label Wellness (No Documented Deficiency)
- 200–300 mcg SC nightly
- Subjective energy, recovery metrics, body composition (patient-reported)
- Varies. Often none beyond initial consult
- This use case does NOT meet 'legitimate medical purpose' criteria in 38+ state jurisdictions. IGF-1 in normal range combined with vague 'optimisation' goals creates prescribing liability for telehealth clinicians
- Pediatric GH Deficiency (Endocrinologist-Managed)
- Weight-based dosing (not applicable to telehealth peptide protocols)
- Linear growth velocity, bone age advancement, IGF-1 normalisation
- Every 3–6 months with pediatric endocrinologist oversight
- Sermorelin is occasionally used off-label in pediatric deficiency states but requires in-person specialist management. Not appropriate for telehealth prescribing